Breathing New Life: The Impact of Incentive Spirometer Training on Rehabilitation and Health in Type 2 Diabetes With Sarcopenia
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 45
- 主要终点
- Lung function:FEV1
研究概览
简要总结
In patients with Type 2 diabetes, the risk of developing sarcopenia is three times higher compared to individuals with normal blood sugar levels. Sarcopenia is often accompanied by reduced physical activity, immobility, slow gait, and poor endurance. More importantly, previous studies have shown that sarcopenia leads to a decrease in mobility, which in turn results in reduced cardiopulmonary function, difficulty in breathing, and subsequently even less activity. In diabetic patients, this can cause poor control of blood sugar and lipids, as well as sarcopenic obesity, creating a vicious cycle. Therefore, preventing such a cycle is a crucial issue that needs attention. The incentive spirometer is widely used in physical, speech, and respiratory therapy, as well as in preventing postoperative pulmonary infections and improving sputum clearance. Consequently, this study aims to further confirm the role and effectiveness of incentive spirometry in improving lung function, activity endurance, and long-term blood sugar and lipid indices in patients with Type 2 diabetes combined with sarcopenia.
详细描述
In patients with Type 2 diabetes, the risk of developing sarcopenia is three times higher compared to individuals with normal blood sugar levels. Sarcopenia is often accompanied by reduced physical activity, immobility, slow gait, and poor endurance. More importantly, previous studies have shown that sarcopenia leads to a decrease in mobility, which in turn results in reduced cardiopulmonary function, difficulty in breathing, and subsequently even less activity. In diabetic patients, this can cause poor control of blood sugar and lipids, as well as sarcopenic obesity, creating a vicious cycle. Therefore, preventing such a cycle is a crucial issue that needs attention. The incentive spirometer is widely used in physical, speech, and respiratory therapy, as well as in preventing postoperative pulmonary infections and improving sputum clearance. Consequently, this study aims to further confirm the role and effectiveness of incentive spirometry in improving lung function, activity endurance, and long-term blood sugar and lipid indices in patients with Type 2 diabetes combined with sarcopenia.
The inclusion criteria:
- Diagnosed with Type 2 diabetes (ICD-10 diagnosis codes: E10.x or E11.x)
- Screened with a score of 4 or above on the screening self-administered sarcopenia (SARC-F) questionnaire.
- Aged between 20-90 years old and able to communicate in Mandarin or Taiwanese
The exclusion criteria:
- Patients with a functional status grade of ≥5 on the Modified Rankin Scale (MRS), indicating severe disability or bedridden condition.
- Patients suffering from dementia, such as Alzheimer's disease, Parkinson's disease, etc.
- Patients with acute psychiatric symptoms unable to communicate.
- Currently diagnosed with chronic obstructive pulmonary disease (COPD) or any other respiratory system diseases.
- Moderate or severe heart disease (New York Heart Association functional classification Class III or IV).
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Supportive Care
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosed with Type 2 diabetes (ICD-10 diagnosis codes: E10.x or E11.x)
- •Screened with a score of 4 or above on the SARC-F questionnaire.
- •Aged between 20-90 years old and able to communicate in Mandarin or Taiwanese
排除标准
- •Patients with a functional status grade of ≥5 on the Modified Rankin Scale (MRS), indicating severe disability or bedridden condition.
- •Patients suffering from dementia, such as Alzheimer's disease, Parkinson's disease, etc.
- •Patients with acute psychiatric symptoms unable to communicate.
- •Currently diagnosed with chronic obstructive pulmonary disease (COPD) or any other respiratory system diseases.
- •Moderate or severe heart disease (New York Heart Association functional classification Class III or IV).
结局指标
主要结局
Lung function:FEV1
时间窗: 3 months
Forced Expiratory Volume in the First Second (FEV1)
Lung function: FEV1/FVC ratio
时间窗: 3 months
FEV1/FVC ratio
Lung function: FVC
时间窗: 3 months
Forced Vital Capacity (FVC)
次要结局
- Long-term Metabolic Indicators: TG(3 months)
- Long-term Metabolic Indicators: HbA1c(3 months)
- Long-term Metabolic Indicators: TC(3 months)
- Long-term Metabolic Indicators: HDL(3 months)
- Long-term Metabolic Indicators: LDL(3 months)
研究者
Yu-Shan Hsieh
Associate professor
National Taipei University of Nursing and Health Sciences